Developer docs
API playgroundTry for free, no card

Search company profiles

PRODROMIC LTD

Full company profile

uuid022nx43

Namestring
PRODROMIC LTD
Legal namestring
Prodromic Limited
Websiteurl
prodromic.ai
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Prodromic Limited is a Cambridge-based AI spin-out from the University of Cambridge that develops a multimodal AI platform for early dementia prediction and patient stratification. Its core technology fuses cognitive tests, health records, structural MRI and PET imaging, genetics (APOE4), blood biomarkers (including Ptau217), and proteomic signals into interpretable patient-level trajectory scores. Models are validated on more than 20,000 patients across 11 global datasets spanning North America, Europe, and Asia, with peer-reviewed evidence in Nature Communications, The Lancet: eClinicalMedicine, and Neuroimage: Clinical, and claimed performance of threefold higher sensitivity than standard approaches at baseline.

The commercial offering consists of an end-to-end SaaS platform and a modular library of ready-to-use AI engines that can be configured for different workflows, from low-cost screening to biomarker-rich precision clinical trials. The company explicitly positions its solutions as research tools rather than regulated medical devices, indicating a research-use commercialization path before any clinical-decision-support deployment. Revenue is generated through platform subscriptions and likely usage-based fees, though no pricing is publicly disclosed.

Prodromic's go-to-market is B2B enterprise, targeting pharmaceutical developers as the primary segment to accelerate and de-risk clinical trials, with secondary motion into clinicians and healthcare systems for early triage and treatment planning. It is founder-led by Professor Zoe Kourtzi (CSO) and Andrew Welchman PhD (CEO), and operates from Milton Hall, Cambridge, with a current team of 1–10 employees and no disclosed venture funding to date.

Short descriptiontext

Prodromic Ltd is a Cambridge spin-out from the University of Cambridge building a multimodal AI platform for early dementia prediction and patient stratification. It serves pharmaceutical developers, clinicians, and healthcare systems with a SaaS research tool validated on 20,000+ patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI dementia prediction, clinical trial stratification, multimodal medical AI, brain health analytics, patient stratification software
Industry5 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
NAICS code3 codes
  • Software Publishers513210
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Prepackaged Software7372
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI-Powered Clinical Predictive Analytics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Platform Subscription
TypeSubscription Recurring
Description

End-to-end SaaS solution providing predictive analytics. Platform processes input data and outputs patient-level predictive scores. Revenue likely generated through platform access and usage fees.

prodromic.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Prodromic provides an end-to-end multimodal AI SaaS platform for early dementia prediction and patient stratification. It ingests cognitive tests, health records, imaging (structural MRI, PET), blood biomarkers (e.g., Ptau217), genetics (APOE4), and proteomic signals to produce interpretable, patient-level scores predicting disease trajectory. A library of ready-to-use AI engines can be deployed across workflows ranging from low-cost screening to biomarker-rich precision clinical trials, helping pharma and clinical partners accelerate trials and improve diagnostic accuracy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Threefold higher sensitivity than standard approaches for distinguishing patient trajectories at baseline
+3 more records
Product overview1 text field

Prodromic offers a unified multimodal AI platform for early dementia prediction. The core Prodromic AI Platform is an end-to-end SaaS solution that processes diverse clinical data sources and outputs interpretable disease trajectory scores. This platform is supported by a library of ready-to-use AI engines trained on different combinations of features, allowing flexible deployment across different clinical workflows—from screening to precision clinical trials.

Product and service2 records
1Prodromic AI Platform
CategoryCore AI SaaS Platform
Description

End-to-end SaaS platform that ingests multimodal clinical data (cognitive tests, health records, imaging, blood biomarkers, genetics, proteomic signals), identifies biologically- and clinically-relevant signals, builds predictions, and outputs easy-to-interpret patient-level scores for dementia trajectory. Targets pharmaceutical developers, clinicians, and healthcare systems for trial design, early triage, and treatment planning.

2AI Engine Library
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Clinicians and Healthcare Providers
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Working with clinicians to accelerate the fight against brain diseases by identifying suitable patients earlier in disease. Focus on embedding AI tools into clinical workflows to improve early triage and treatment outcomes.

prodromic.ai
2Academic Institutions
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with academic researchers to accelerate new treatments and generate better biological insights into brain health. Based on decade of research from University of Cambridge.

prodromic.ai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with pharma developers to accelerate clinical trials by identifying suitable patients earlier. Prodromic's technology makes trials faster, lower-cost, and more effective by enabling better patient stratification.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

UK-based neuroscience-focused company (CANTAB) providing computerised cognitive assessments and digital biomarkers widely used in pharma-sponsored dementia and CNS clinical trials — highly comparable use case (trial stratification) and product category.

2IXICO
TypeDirect peer
Description

UK-based neuroimaging analytics company providing AI-enabled MRI/PET analysis and biomarker services for neurodegenerative disease clinical trials — comparable imaging-AI capability and pharma-trial customer base.

TypeDirect peer
Description

Commercial-stage digital cognition company offering computerised tests for use in clinical trials (notably Alzheimer's and other CNS indications) and healthcare — directly overlapping product offering (cognitive testing for trials) and target customers (pharma developers).

TypeDirect peer
Description

US/Swiss digital neurology company using AR-based assessments and AI/ML to generate digital biomarkers predicting conversion from MCI to Alzheimer's — overlapping patient-stratification and clinical-trial use case in the dementia space.

TypeDirect peer
Description

Boston-based digital health company combining AI-driven digital cognitive assessments (e.g., DCTclock, voice-based tests) with multi-modal data for early brain health evaluation, clinical trial stratification, and dementia risk detection — directly comparable offering and customer base (pharma + clinicians).

TypeBroad incumbent
Description

Large clinical-trial technology vendor offering imaging, eCOA, and CNS/neurodegenerative trial services across pharma — overlapping customer base and broad portfolio including imaging analytics used for trial stratification.

TypeDirect peer
Description

UK-based neuroscience platform combining at-home digital cognitive testing, speech, and physiology data with analytics to generate biomarkers for CNS clinical trials — comparable multi-modal patient-stratification offering for pharma trials.

TypeEmerging player
Description

US-based AI neuroimaging company (BrainSee) using non-invasive MRI to predict Alzheimer's disease onset years before symptoms — overlapping multi-modal imaging AI approach and dementia focus, but earlier-stage and narrower modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PRODROMIC LTD

AI-Powered Clinical Predictive Analyticsprodromic.ai

Prodromic Ltd is a Cambridge spin-out from the University of Cambridge building a multimodal AI platform for early dementia prediction and patient stratification. It serves pharmaceutical developers, clinicians, and healthcare systems with a SaaS research tool validated on 20,000+ patients.

What PRODROMIC LTD does

Prodromic Limited is a Cambridge-based AI spin-out from the University of Cambridge that develops a multimodal AI platform for early dementia prediction and patient stratification. Its core technology fuses cognitive tests, health records, structural MRI and PET imaging, genetics (APOE4), blood biomarkers (including Ptau217), and proteomic signals into interpretable patient-level trajectory scores. Models are validated on more than 20,000 patients across 11 global datasets spanning North America, Europe, and Asia, with peer-reviewed evidence in Nature Communications, The Lancet: eClinicalMedicine, and Neuroimage: Clinical, and claimed performance of threefold higher sensitivity than standard approaches at baseline.

The commercial offering consists of an end-to-end SaaS platform and a modular library of ready-to-use AI engines that can be configured for different workflows, from low-cost screening to biomarker-rich precision clinical trials. The company explicitly positions its solutions as research tools rather than regulated medical devices, indicating a research-use commercialization path before any clinical-decision-support deployment. Revenue is generated through platform subscriptions and likely usage-based fees, though no pricing is publicly disclosed.

Prodromic's go-to-market is B2B enterprise, targeting pharmaceutical developers as the primary segment to accelerate and de-risk clinical trials, with secondary motion into clinicians and healthcare systems for early triage and treatment planning. It is founder-led by Professor Zoe Kourtzi (CSO) and Andrew Welchman PhD (CEO), and operates from Milton Hall, Cambridge, with a current team of 1–10 employees and no disclosed venture funding to date.

PRODROMIC LTD firmographics

Firmographics
Name
PRODROMIC LTD
Legal name
Prodromic Limited
Website
https://prodromic.ai
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Prodromic Ltd is a Cambridge spin-out from the University of Cambridge building a multimodal AI platform for early dementia prediction and patient stratification. It serves pharmaceutical developers, clinicians, and healthcare systems with a SaaS research tool validated on 20,000+ patients.
Ownership category
akta.pro rank

PRODROMIC LTD industry classification

Industry
Product category
AI-Powered Clinical Predictive Analytics
NAICS
Software Publishers (513210), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Keywords

  • AI dementia prediction
  • Clinical trial stratification
  • Multimodal medical AI
  • Brain health analytics
  • Patient stratification software

Where PRODROMIC LTD is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

PRODROMIC LTD business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. SaaS Platform Subscription: End-to-end SaaS solution providing predictive analytics. Platform processes input data and outputs patient-level predictive scores. Revenue likely generated through platform access and usage fees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

PRODROMIC LTD product offering

Product offering

Core offering

Prodromic provides an end-to-end multimodal AI SaaS platform for early dementia prediction and patient stratification. It ingests cognitive tests, health records, imaging (structural MRI, PET), blood biomarkers (e.g., Ptau217), genetics (APOE4), and proteomic signals to produce interpretable, patient-level scores predicting disease trajectory. A library of ready-to-use AI engines can be deployed across workflows ranging from low-cost screening to biomarker-rich precision clinical trials, helping pharma and clinical partners accelerate trials and improve diagnostic accuracy.

Product overview

Prodromic offers a unified multimodal AI platform for early dementia prediction. The core Prodromic AI Platform is an end-to-end SaaS solution that processes diverse clinical data sources and outputs interpretable disease trajectory scores. This platform is supported by a library of ready-to-use AI engines trained on different combinations of features, allowing flexible deployment across different clinical workflows—from screening to precision clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Prodromic AI Platform End-to-end SaaS platform that ingests multimodal clinical data (cognitive tests, health records, imaging, blood biomarkers, genetics, proteomic signals), identifies biologically- and clinically-relevant signals, builds predictions, and outputs easy-to-interpret patient-level scores for dementia trajectory. Targets pharmaceutical developers, clinicians, and healthcare systems for trial design, early triage, and treatment planning.
  • AI Engine Library

Quantifiable outcome

  • Threefold higher sensitivity than standard approaches for distinguishing patient trajectories at baseline
  • +3 more outcomes

Companies that use PRODROMIC LTD

Customer profile

Segments2 records

Ideal customer profiles2 records

PRODROMIC LTD technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

PRODROMIC LTD partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Clinicians and Healthcare ProviderscoreStrategic or Co-development PartnerWorking with clinicians to accelerate the fight against brain diseases by identifying suitable patients earlier in disease. Focus on embedding AI tools into clinical workflows to improve early triage and treatment outcomes.
  • Academic InstitutionscoreStrategic or Co-development PartnerCollaboration with academic researchers to accelerate new treatments and generate better biological insights into brain health. Based on decade of research from University of Cambridge.
  • Pharmaceutical DeveloperscoreStrategic or Co-development PartnerPartnership with pharma developers to accelerate clinical trials by identifying suitable patients earlier. Prodromic's technology makes trials faster, lower-cost, and more effective by enabling better patient stratification.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

PRODROMIC LTD competitors and assessment

Company assessment

Direct peers

  • Cambridge Cognition: UK-based neuroscience-focused company (CANTAB) providing computerised cognitive assessments and digital biomarkers widely used in pharma-sponsored dementia and CNS clinical trials — highly comparable use case (trial stratification) and product category.
  • IXICO: UK-based neuroimaging analytics company providing AI-enabled MRI/PET analysis and biomarker services for neurodegenerative disease clinical trials — comparable imaging-AI capability and pharma-trial customer base.
  • Cogstate: Commercial-stage digital cognition company offering computerised tests for use in clinical trials (notably Alzheimer's and other CNS indications) and healthcare — directly overlapping product offering (cognitive testing for trials) and target customers (pharma developers).
  • Altoida: US/Swiss digital neurology company using AR-based assessments and AI/ML to generate digital biomarkers predicting conversion from MCI to Alzheimer's — overlapping patient-stratification and clinical-trial use case in the dementia space.
  • Linus Health: Boston-based digital health company combining AI-driven digital cognitive assessments (e.g., DCTclock, voice-based tests) with multi-modal data for early brain health evaluation, clinical trial stratification, and dementia risk detection — directly comparable offering and customer base (pharma + clinicians).
  • Cumulus Neuroscience: UK-based neuroscience platform combining at-home digital cognitive testing, speech, and physiology data with analytics to generate biomarkers for CNS clinical trials — comparable multi-modal patient-stratification offering for pharma trials.

Broad incumbents

  • Clario (formerly Bioclinica): Large clinical-trial technology vendor offering imaging, eCOA, and CNS/neurodegenerative trial services across pharma — overlapping customer base and broad portfolio including imaging analytics used for trial stratification.

Emerging players

  • Darmiyan: US-based AI neuroimaging company (BrainSee) using non-invasive MRI to predict Alzheimer's disease onset years before symptoms — overlapping multi-modal imaging AI approach and dementia focus, but earlier-stage and narrower modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

PRODROMIC LTD social profiles

Digital presence

PRODROMIC LTD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PRODROMIC LTD leadership team

Management profile

Number of profiles

Profiles2 records

PRODROMIC LTD funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PRODROMIC LTD M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRODROMIC LTD

What does PRODROMIC LTD do?

Prodromic provides an end-to-end multimodal AI SaaS platform for early dementia prediction and patient stratification. It ingests cognitive tests, health records, imaging (structural MRI, PET), blood biomarkers (e.g., Ptau217), genetics (APOE4), and proteomic signals to produce interpretable, patient-level scores predicting disease trajectory. A library of ready-to-use AI engines can be deployed across workflows ranging from low-cost screening to biomarker-rich precision clinical trials, helping pharma and clinical partners accelerate trials and improve diagnostic accuracy.

Is PRODROMIC LTD a public or private company?

PRODROMIC LTD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was PRODROMIC LTD founded?

PRODROMIC LTD was founded in -1. It employs 1 to 10 people.

Where is PRODROMIC LTD based?

PRODROMIC LTD is headquartered in Cambridge, United Kingdom, in the Europe region.

How does PRODROMIC LTD make money?

One revenue line is on record: saaS Platform Subscription.

Who are PRODROMIC LTD's main competitors?

Direct peers on record are Cambridge Cognition, IXICO, Cogstate, Altoida, Linus Health and Cumulus Neuroscience. Clario (formerly Bioclinica) is listed as a broad incumbent. Darmiyan is listed as an emerging player.

Does PRODROMIC LTD have an API?

No public API is recorded for PRODROMIC LTD.

What industry is PRODROMIC LTD in?

PRODROMIC LTD's product category is AI-Powered Clinical Predictive Analytics. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales